Differentiation between Systolic and Diastolic Dysfunction

Left ventricular (LV) failure can be divided into systolic and diastolic dysfunction. The former is characterized by a reduced ejection fraction and an enlarged LV chamber, the latter by an increased resistance to filling with increased filling pressures. Systolic dysfunction is clinically associated with left ventricular failure in the presence of marked cardiomegaly, while diastolic dysfunction is accompanied by pulmonary congestion together with a normal or only slightly enlarged ventricle. Echocardiography is currently the most relevant technique for non-invasive differentiation of the two forms. Systolic dysfunction is easily assessable by estimation of global ejection fraction and regional wall motion. Diastolic dysfunction can be diagnosed indirectly by means of a normal or nearly normal ejection fraction and changes of the mitral filling pattern in the context of LV failure. For an exact determination of diastolic dysfunction LV catheterization is required. Systolic dysfunction treatment is well defined, consisting of ACE inhibitors, followed by diuretics and digitalis. Calcium channel blockers are usually contraindicated. Diastolic dysfunction therapy is more dependent on the underlying disease. Calcium channel blockers, ACE inhibitors or beta-blockers are first line drugs in most instances: diuretics can be added with increasing symptoms. Digitalis should be avoided, except in atrial fibrillation, to control heart rat

Measurement of the hyperfine structure of antihydrogen in a beam

A measurement of the hyperfine structure of antihydrogen promises one of the best tests of CPT symmetry. We describe an experiment planned at the Antiproton Decelerator of CERN to measure this quantity in a beam of slow antihydrogen atoms.Comment: 5th International Symposium on Symmetries in Subatomic Physics (SSP2012), Groningen (The Netherlands), June 18 to 22, 201

Formation and dynamics of van der Waals molecules in buffer-gas traps

We show that weakly bound He-containing van der Waals molecules can be produced and magnetically trapped in buffer-gas cooling experiments, and provide a general model for the formation and dynamics of these molecules. Our analysis shows that, at typical experimental parameters, thermodynamics favors the formation of van der Waals complexes composed of a helium atom bound to most open-shell atoms and molecules, and that complex formation occurs quickly enough to ensure chemical equilibrium. For molecular pairs composed of a He atom and an S-state atom, the molecular spin is stable during formation, dissociation, and collisions, and thus these molecules can be magnetically trapped. Collisional spin relaxations are too slow to affect trap lifetimes. However, helium-3-containing complexes can change spin due to adiabatic crossings between trapped and untrapped Zeeman states, mediated by the anisotropic hyperfine interaction, causing trap loss. We provide a detailed model for Ag3He molecules, using ab initio calculation of Ag-He interaction potentials and spin interactions, quantum scattering theory, and direct Monte Carlo simulations to describe formation and spin relaxation in this system. The calculated rate of spin-change agrees quantitatively with experimental observations, providing indirect evidence for molecular formation in buffer-gas-cooled magnetic traps.Comment: 20 pages, 13 figure

Overview of the IWSLT 2017 Evaluation Campaign

The IWSLT 2017 evaluation campaign has organised three tasks. The Multilingual task, which is about training machine translation systems handling many-to-many language directions, including so-called zero-shot directions. The Dialogue task, which calls for the integration of context information in machine translation, in order to resolve anaphoric references that typically occur in human-human dialogue turns. And, finally, the Lecture task, which offers the challenge of automatically transcribing and translating real-life university lectures. Following the tradition of these reports, we will described all tasks in detail and present the results of all runs submitted by their participants

ASACUSA Status Report

ASACUSA progress during 2009 and plans for 201

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study

BACKGROUND: We report a prospective multicenter phase II study of haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3. DESIGN AND METHODS: Sixty-one adults with a median age of 46 years (range 19-65 years) have been enrolled. Diagnoses were acute myeloid leukemia (n=38), acute lymphoblastic leukemia (n=8), non-Hodgkin's lymphoma (n=6), myeloma (n=4), chronic myeloid leukemia (n=3), chronic lymphatic leukemia (n=1) and myelodysplastic syndrome (n=1). Patients were considered high risk because of refractory disease (n=18), cytogenetics (n=6), complete remission (≥2) (n=9), chemosensitive relapse in partial remission (n=4) or relapse after prior hematopoietic stem cell transplantation (n=15 allogeneic, n=8 autologous, n=1 both). At haploidentical hematopoietic stem cell transplantation, 30 patients were in complete remission and 31 in partial remission. Grafts contained a median of 7.0×10(6) (range 3.2-22) CD34(+) cells/kg, 4.2×10(4) (range 0.6-44) CD3(+) T cells/kg and 2.7×10(7) (range 0.00-37.3) CD56(+) cells/kg. RESULTS: Engraftment was rapid with a median of 12 days to granulocytes more than 0.5×10(9)/L (range 9-50 days) and 11 days to platelets more than 20×10(9) (range 7-38 days). Incidence of grade IIIV acute graft-versus-host-disease and chronic graft-versus-host-disease was 46% and 18%, respectively. Non-relapse mortality on Day 100 was 23% and 42% at two years. Cumulative incidence of relapse/progression at two years was 31%. Kaplan-Meier estimated 1-year and 2-year overall survival with median follow up of 869 days (range 181-1932) is 41% and 28%, respectively. CONCLUSIONS: This regimen allows successful haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning in high-risk patients lacking a suitable donor. (clinicaltrials.gov identifier:NCT00202917)